Related references
Note: Only part of the references are listed.High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens
H. S. Han et al.
ANNALS OF ONCOLOGY (2009)
Fat necrosis mimicking B-cell lymphoma - A PET/CT and FDG study
Abdeffiatihe Belakhlef et al.
CLINICAL NUCLEAR MEDICINE (2008)
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-Cell lymphoma with analysis of germinal center and post-germinal center biomarkers
Wyndham H. Wilson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
False positive PET scanning caused by inactivated influenza virus vaccination during complete remission from anaplastic T-cell lymphoma
Daniele Focosi et al.
ANNALS OF HEMATOLOGY (2008)
Extensive FDG uptake and its modification with corticosteroid in a granuloma rat model: an experimental study for differentiating granuloma from tumors
Songji Zhao et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
False-positive FDG-PET findings clue to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma
Yuko Inoue et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn et al.
BLOOD (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma
Malik E. Juweid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study
Christophe Fruchart et al.
LEUKEMIA & LYMPHOMA (2006)
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma
Clyde D. Ford et al.
CLINICAL NUCLEAR MEDICINE (2006)
The inconsistency of optimal cutpoints obtained using two criteria based on the receiver operating characteristic curve
NJ Perkins et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
M Hutchings et al.
BLOOD (2006)
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma:: an early prognostic tool for predicting patient outcome
C Haioun et al.
BLOOD (2005)
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
LH Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
ME Juweid et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas:: results of the NHL-B1 trial of the DSHNHL
M Pfreundschuh et al.
BLOOD (2004)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:: results of the NHL-B2 trial of the DSHNHL
M Pfreundschuh et al.
BLOOD (2004)
From the bench to the bedside: ways to improve rituximab efficacy
G Cartron et al.
BLOOD (2004)
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
T Kewalramani et al.
BLOOD (2004)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
K Spaepen et al.
ANNALS OF ONCOLOGY (2002)
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy
WH Wilson et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma:: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
K Spaepen et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
